Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT03935282 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in community oncology practices, using a group-randomized trial design (6 intervention practices and 6 usual care practices). Our central hypothesis is that the AH-HA tool will increase (1) cardiovascular health (CVH) discussions among survivors and oncology providers, (2) referrals and visits to primary care and cardiology (care coordination), and (3) cardiovascular (CV) risk reduction and health promotion activities compared to usual care.

Interventions

  • OTHER AH-HA Tool in the EPIC EHR

Study Locations (12)

Missouri

  • Saint Louis Cancer and Breast Institute-Ballwin — Ballwin
  • Mercy Hospital Springfield — Springfield
  • Mercy Hospital Saint Louis — St Louis

Pennsylvania

  • Community Medical Center — Scranton
  • Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre

Tennessee

  • Baptist Memorial Hospital and Cancer Center-Memphis — Memphis
  • Baptist Memorial Hospital for Women — Memphis

Arkansas

  • Mercy Hospital Fort Smith — Fort Smith

Iowa

  • Oncology Associates at Mercy Medical Center — Cedar Rapids

Oklahoma

  • Mercy Hospital Oklahoma City — Oklahoma City

Virginia

  • Virginia Commonwealth University/Massey Cancer Center — Richmond

Wisconsin

  • ThedaCare Regional Cancer Center — Appleton

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2020-10-01
Est. Completion 2025-11-17
Phase NA

Sponsor

Wake Forest University Health Sciences

1,061 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03935282

The ClinicalTrials.gov registry entry for NCT03935282 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,061 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention — of which AH-HA Tool in the EPIC EHR is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03935282 reports 12 study locations spanning 8 distinct geographic areas — top geographies include Missouri, Pennsylvania, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03935282 about?

NCT03935282 is a clinical study titled "Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors". The objective of this hybrid effectiveness-implementation study is to examine the effects of an EHR-based cardiovascular health assessment tool (AH-HA) among breast, prostate, colorectal, endometrial, and Hodgkin and non-Hodgkin lymphoma cancer survivors (N=600) receiving survivorship care in commun...

What is the current status of trial NCT03935282?

This trial is currently completed. It is a NA study. The enrollment target is 600 participants. The study started on 2020-10-01. Estimated completion is 2025-11-17.

What conditions does trial NCT03935282 study?

This clinical trial studies the following conditions: Colorectal Neoplasms, Non Hodgkin Lymphoma, Breast Neoplasm, Hodgkin Disease, Endometrial Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03935282?

The interventions under investigation include: AH-HA Tool in the EPIC EHR (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03935282?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,061 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03935282 being conducted?

This trial has 12 study locations across Arkansas, Iowa, Missouri, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial